These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25900790)

  • 21. Lichenoid eruption due to imatinib.
    Prabhash K; Doval DC
    Indian J Dermatol Venereol Leprol; 2005; 71(4):287-8. PubMed ID: 16394444
    [No Abstract]   [Full Text] [Related]  

  • 22. Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression.
    Inami M; Inokuchi K; Yamaguchi H; Nakayama K; Watanabe A; Uchida N; Tanosaki S; Dan K
    Int J Hematol; 2006 Nov; 84(4):346-53. PubMed ID: 17118762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical progress in chronic myelogenous leukemia].
    Matsunaga T
    Rinsho Ketsueki; 2009 Oct; 50(10):1489-99. PubMed ID: 19915358
    [No Abstract]   [Full Text] [Related]  

  • 25. [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].
    Zhang Y; Qin TJ; Zhou CL; Liu L; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):381-4. PubMed ID: 19951530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
    Philips ST; Hildenbrand ZL; Oravecz-Wilson KI; Foley SB; Mgbemena VE; Ross TS
    Oncogene; 2014 Nov; 33(46):5379-90. PubMed ID: 24240679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
    Berger U; Hehlmann R
    Internist (Berl); 2004 Jan; 45(1):102-3. PubMed ID: 14735248
    [No Abstract]   [Full Text] [Related]  

  • 29. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
    Yeung DT; Osborn MP; White DL; Branford S; Braley J; Herschtal A; Kornhauser M; Issa S; Hiwase DK; Hertzberg M; Schwarer AP; Filshie R; Arthur CK; Kwan YL; Trotman J; Forsyth CJ; Taper J; Ross DM; Beresford J; Tam C; Mills AK; Grigg AP; Hughes TP;
    Blood; 2015 Feb; 125(6):915-23. PubMed ID: 25519749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
    Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
    Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
    Lierman E; Smits S; Cools J; Dewaele B; Debiec-Rychter M; Vandenberghe P
    Leukemia; 2012 Jul; 26(7):1693-5. PubMed ID: 22301675
    [No Abstract]   [Full Text] [Related]  

  • 32. Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
    Delomas T; Darné C; Besson C
    Leuk Lymphoma; 2012 Feb; 53(2):332-3. PubMed ID: 21823828
    [No Abstract]   [Full Text] [Related]  

  • 33. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd.
    Nakamae H; Shibayama H; Kurokawa M; Fukuda T; Nakaseko C; Kanda Y; Nagai T; Ohnishi K; Maeda Y; Matsuda A; Amagasaki T; Yanada M
    Int J Hematol; 2011 May; 93(5):624-632. PubMed ID: 21523338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The results of imatinib therapy for patients with primary eosinophilic disorders.
    Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
    Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
    [No Abstract]   [Full Text] [Related]  

  • 35. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
    Neelakantan P; Rezvani K; May P; Gerrard G; Marco B; Paliompeis C; Reid A; Goldman J; Marin D; Milojkovic D
    Br J Haematol; 2014 Feb; 164(4):608-10. PubMed ID: 24219400
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib.
    Ikezoe T; Togitani K; Tasaka T; Nishioka C; Yokoyama A
    Leuk Res; 2010 Aug; 34(8):e200-1. PubMed ID: 20303172
    [No Abstract]   [Full Text] [Related]  

  • 37. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 38. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.
    Perna F; Abdel-Wahab O; Levine RL; Jhanwar SC; Imada K; Nimer SD
    Haematologica; 2011 Feb; 96(2):342-3. PubMed ID: 21193423
    [No Abstract]   [Full Text] [Related]  

  • 39. Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.
    Barraco D; Carobolante F; Candoni A; Simeone E; Piccaluga P; Tabanelli V; Fanin R
    Eur J Haematol; 2014 Jun; 92(6):541-5. PubMed ID: 24460680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ
    J Natl Cancer Inst; 2003 Aug; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.